CDA-AMC Reimbursement Review 1

Provisional Funding 2 Algorithm 3

Indication: Multiple Myeloma 4

5

8

- This report supersedes the CADTH Provisional funding algorithm report for Multiple Myeloma 6 dated July 2023. 7
- Please always check CADTH Provisional Funding Algorithms | CADTH to ensure you are reading 9 the most recent algorithm report. 10

Service Line: Version: Publication Date: Report Length:

18 19 CDA-AMC Reimbursement Review Draft Date 17 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the *Canadian Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

21	Background
22 23 24 25 26	Following a request from jurisdictions, CADTH may design or update an algorithm depicting the sequence of funded treatments for a particular tumour type. These algorithms are proposals for the jurisdictions to implement and adapt to the local context. As such, they are termed "provisional." Publishing of provisional algorithms is meant to improve transparency of the oncology drug funding process and promote consistency across jurisdictions.
27	Provisional funding algorithms are based on 3 principal sources of information:
28	 CADTH pCODR Expert Review Committee (pERC) reimbursement
29	recommendations and/or implementation guidance regarding drug place in therapy
30	and sequencing
31	 implementation advice from panels of clinicians convened by CADTH concerning
32	sequencing of drugs in the therapeutic space of interest
33	 existing oncology drug reimbursement criteria and legacy funding algorithms
34	adopted by jurisdictional drug plans and cancer agencies.
35 36 37 38 39 40	Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management of each patient nor the provision of each drug regimen. The diagrams may not contain a comprehensive list of all available treatments, and some drugs may not be funded in certain jurisdictions. All drugs are subject to explicit funding criteria, which may also vary between jurisdictions. Readers are invited to refer to the cited sources of information on the CADTH website for more details.
41 42 43 44	Provisional funding algorithms also delineate treatment sequences available to patients who were never treated for the condition of interest (i.e., incident population). Time-limited funding of new options for previously or currently treated patients (i.e., prevalent population) is not detailed in the algorithm.
45	Provisional funding algorithms may contain drugs that are under consideration for funding.
46	Algorithms will not be dynamically updated by CADTH following changes to drug funding
47	status. Revisions and updates will occur only upon request by jurisdictions.
48	Jurisdictional cancer drug programs requested a CADTH provisional funding
49	algorithm on multiple myeloma. However, no outstanding implementation issues
50	were identified, and no additional implementation advice is provided in this report.
51	The algorithm depicted herein is meant to reflect the current and anticipated funding
52	landscape based on the previously mentioned sources of information.

History and Development of the Provisional Funding Algorithm

To-date, CADTH has published two provisional funding algorithm reports for multiple myeloma. The first report was published in May 2022 which was a panel algorithm. The second report was a rapid algorithm published in November to update and incorporate the CADTH recommendation for Selinexor.

In May 2023, jurisdictional cancer drug programs requested an update to the rapid algorithm to incorporate the CADTH recommendation for ciltacabtagene autoleucel (Carvykti), the first CAR T-cell therapy approved for the treatment of adult patients with multiple myeloma.

In June 2024, jurisdictional cancer drug programs requested an update to the rapid algorithm to incorporate CADTH recommendations for teclistamab (Tecvayli) and elranatamab (Elrexfio).

Table 1: Relevant CADTH Recommendations

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
	Newl	y diagnosed
Daratumumab (Darzalex) + lenalidomide (Revlimid) + dexamethasone	Mar 5, 2020	 pERC conditionally recommends to reimburse daratumumab in combination with lenalidomide and dexamethasone (DRd) for patients with newly diagnosed MM who are not suitable for autologous stem cell transplant if the following conditions are met: cost-effectiveness being improved to an acceptable level feasibility of adoption (budget impact) being addressed. pERC concluded that the optimal sequencing of therapies for patients with newly diagnosed MM who are not suitable for autologous stem cell transplant is unknown. Therefore, pERC was unable to make an evidence-informed recommendation on sequencing of treatments. pERC recognized that provinces will need to address this issue upon implementation of a reimbursement recommendation for DRd and noted that collaboration among provinces to develop a national, uniform approach to optimal sequencing would be of great value.
Lenalidomide (Revlimid) + bortezomib (Velcade) + Dexamethasone	<u>June 19, 2019</u>	 pERC conditionally recommends to reimburse lenalidomide in combination with bortezomib and low-dose dexamethasone in patients with newly diagnosed MM in whom stem cell transplantation is not intended if the following condition is met: feasibility of adoption is addressed (budget impact). Reimbursement should be in patients with good performance status and treatment (with lenalidomide or low-dose dexamethasone for the maintenance phase) should continue until unacceptable toxicity or disease progression. pERC concluded that the optimal sequencing of therapies for patients with newly diagnosed MM in whom stem cell transplantation is not intended is unknown. Therefore, pERC was unable to make an evidence-based recommendation on sequencing of treatments. pERC recognizes that provinces will need to address this issue upon implementation of a reimbursement recommendation for VLd, and noted that collaboration among provinces to develop a national, uniform approach to optimal sequencing would be of great value.

Generic name	Date of	Recommendation and guidance on treatment
(brand name)	recommendation	sequencing
Daratumumab (Darzalex) + bortezomib (Velcade) + melphalan + prednisone	August 29, 2019	pERC conditionally recommends to reimburse daratumumab in combination with bortezomib, melphalan, and prednisone (DVMp) for patients with newly diagnosed MM who are not suitable for ASCT if the following conditions are met:
		 cost-effectiveness being improved to an acceptable level feasibility of adoption (budget impact) being addressed treatment with daratumumab should continue until unacceptable toxicity or disease progression Optimal sequencing of available therapies after progression on daratumumab in combination with bortezomib, melphalan, and prednisone:
		pERC concluded that the optimal sequencing of therapies for patients with newly diagnosed MM who are not suitable for ASCT is unknown. Therefore, pERC was unable to make an evidence- based recommendation on sequencing of treatments. pERC recognizes that provinces will need to address this issue upon implementation of a reimbursement recommendation for daratumumab and noted that collaboration among provinces to develop and national, uniform approach to optimal sequencing would be of great value.
		Daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone:
		At the time of implementing a reimbursement recommendation for DVMp, jurisdictions may consider extending the reimbursement to daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (DCyBord) because pERC agreed with the registered clinician input and the CGP that DCyBord would likely be equally as effective as DVMp and possibly less toxic.
	Relapse	ed or refractory
Elranatamab (Elrexfio)	June 2024	 CADTH recommends that elranatamab should be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy if the following conditions are met: Initiation 1. Elranatamab should be reimbursed in adult patients aged 18 years or older who meet all the following criteria: 1.1 documented diagnosis of MM 1.2 documented evidence of progressive disease within the previous 6 months 1.3 received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody 1.4 no prior exposure to BCMA-directed therapy 1.5 refractory to their last treatment 1.6 good performance status 2. Elranatamab should not be initiated in patients with active CNS involvement or exhibiting signs of meningeal involvement of

Generic name (brand name) Date of recommendation Recommendation and guidance on treatment sequencing Discontinuation 3. Treatment with elranatamab should be discontinued up occurrence of any of the following, whichever occurs fin 3.1. disease progression 3.2. unacceptable toxicity Prescribing 4. Elranatamab should be administered by health profess at treatment centres with adequate medical resources a personnel to manage severe reactions, including cytoki release syndrome and neurologic toxicities. Pricing 5. A reduction in price. Feasibility of adoption Feasibility of adoption	
Discontinuation 3. Treatment with elranatamab should be discontinued up occurrence of any of the following, whichever occurs fir 3.1. disease progression 3.2. unacceptable toxicity Prescribing 4. Elranatamab should be administered by health profess at treatment centres with adequate medical resources a personnel to manage severe reactions, including cytoki release syndrome and neurologic toxicities. Pricing 5. A reduction in price.	
 6. The feasibility of adoption of elranatamab must be addi 7. The organizational feasibility of jurisdictions having spe treatment centres with the infrastructure and resources required to administer elranatamab and manage adver events must be addressed. Guidance on sequencing or treatment considerations: pERC acknowledged that clinicians may consider using elranatamab for patients with an ECOG performance status their discretion. pERC recognized that tocilizumab must be readily available treatment of CRS. The product monograph recommends monitoring patients for and neurologic toxicity, including ICANS, and states that elranatamab should be administered by a health care profer with appropriate medical support to manage these severe reactions. Although pERC acknowledged that clinical experts thought be reasonable to consider patients previously treated with E targreted therapy (e.g., CAR T-cell therapy) eligible for elran pERC also noted that there is limited evidence to support th pERC anditionally noted that there is denote to support the patients previously treated with elranatamab. pERC noted that there is no evidence reviewed to inform th elranatamab is for the treatment of adult patients with relaps refractory multiple myeloma who have received at least 3 pp refractory multiple myeloma who have received at least 3 pot therapy, pERC acknowledged the elinical experts' opini patients two are resistant to PLs, an immunomodulatory agy an anti-CD38 antibody (i.e., all 3), or intolerant to any of the resistant to the others should be eligible to reerise and who have demonstrated disease progression last therapy. pERC acknowledged the anti-cD38 monoclona antibody, and what line of therapy it is in, however, this woul outside of the Health Canada indication and therefore pER not recommend this. 	st: onals and ne essed. cialized se ≥ 2 at for the or CRS asional t would CMA- atamab, is. d in this v in e use of lth sed or ior lines l on the on that ent, and mab, d be

Conorio namo	Date of	Recommendation and guidance on treatment
Generic name (brand name)	recommendation	sequencing
		One of the clinical experts noted that they would likely prioritise cilta-cel before a bispecific if there are no clinical or logistical issues.
		The clinical experts noted that the toxicity profile and likelihood of CRS could be a consideration. They indicated that elranatamab is given subcutaneously which could be an advantage over the other therapies where infusion access is limited, although elranatamab still needs to be given in a trained infusion or chemotherapy unit. They also noted that using a bispecific over CAR T-cell therapy may be necessary when geographic access or capacity is an issue and where immediate treatment is required.
		pERC agreed that treatment selection would rely on patient and logistical factors.
Teclistamab (Tecvayli)	<u>April 24, 2024</u>	CADTH recommends that teclistamab be reimbursed by public drug plans for the treatment of adults with relapsed or refractory (r/r) multiple myeloma (MM) who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody (mAb), and who have demonstrated disease progression on the last therapy if the following conditions are met:
		 Initiation Teclistamab should be reimbursed in adults aged 18 years or older who meet all the following criteria: 1.1 documented diagnosis of MM 2.2 documented evidence of progressive disease within the previous 6 months
		Discontinuation
		 Treatment with teclistamab should be discontinued upon any of the following, whichever occurs first: 3.1 disease progression 3.2 unacceptable toxicity. Prescribing
		4. Teclistamab should be administered by health professionals at treatment centres with adequate medical resources and personnel to manage severe reactions, including cytokine release syndrome and neurologic toxicities.
		Pricing
		5. A reduction in price
		Feasibility of adoption
		6. Feasibility of adoption of teclistamab must be addressed.

Generic name	Date of	Recommendation and guidance on treatment
(brand name)	recommendation	sequencing
		Guidance on sequencing or treatment considerations: pERC acknowledged that clinicians may consider using teclistamab for patients with an ECOG PS ≥ 2 at their discretion.
		pERC recognized that access to tocilizumab for the treatment of cytokine release syndrome is necessary.
		While pERC agreed with the clinical experts that it would be reasonable to consider patients previously treated with a BCMA- targeted therapy (e.g., CAR T-cell therapy) eligible for teclistamab, pERC noted that there is limited evidence to support this. pERC additionally noted that there was no evidence included in this CADTH review to support the appropriateness of CAR T-cell therapy in patients previously treated with teclistamab.
		There is no evidence reviewed to inform the use of teclistamab in early lines of therapy. Aligned with the Health Canada–approved indication, the reimbursement request for teclistamab is for the treatment of adults with r/r MM who have received at least 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy. pERC acknowledged the clinical experts' opinion that patients who are resistant to PIs, an IMiD, and an anti-CD38 mAb (i.e., all 3), or are intolerant to any of them and resistant to the others should be eligible to receive teclistamab, regardless of what line of therapy it is in.
Ciltacabtagene autoleucel (Carvykti)	<u>May 17, 2023</u>	pERC recommends that ciltacabtagene autoleucel be reimbursed for the treatment of adult patients with MM, who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment only if the following conditions are met:
		Initiation
		 Ciltacabtagene autoleucel should be reimbursed in adult patients aged 18 years or older who meet all the following criteria: Documented diagnosis of MM. Received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Refractory to their last treatment. Have good performance status.
		 Ciltacabtagene autoleucel should not be initiated in patients with active CNS involvement or exhibiting signs of meningeal involvement of MM.
		 Ciltacabtagene autoleucel should not be reimbursed in patients who have received prior treatment with any therapy that is targeted to BCMA or any CAR-T cell therapy.
		Prescribing
		 Treatment with ciltacabtagene autoleucel is a one-time therapy.

Generic name	Date of	Recommendation and guidance on treatment
(brand name)	recommendation	sequencing
		 Ciltacabtagene autoleucel should only be prescribed by clinicians with expertise in the treatment of MM. Ciltacabtagene autoleucel should be administered in specialized centres with adequate infrastructure, resources, and expertise to facilitate treatment with CAR T-cell therapy.
		Pricing
		6. A reduction in price.
		Feasibility of adoption
		7. The feasibility of adoption of ciltacabtagene autoleucel must be addressed.
		Guidance on Sequencing
		If capacity limitations exist, how would you prioritize which patients should be offered ciltacabtagene autoleucel?
		pERC could not comment on how to prioritize which patients should be offered ciltacabtagane autoleucel as it was outside of the scope of this review.
		Is there a time-limited need to consider patients who were not able to access anti-CD38 (e.g., patients previously treated with the RVd regimen whose disease ended up being refractory to both lenalidomide and bortezomid)?
		The clinical experts indicated that it is important to include those patients who have not had the three classes of treatment due to lack of funded access to anti-CD38 antibodies. The clinical experts noted they would not expect the outcome of treatment with <u>ciltacabtagene autoleucel</u> to be inferior in these patients compared to patients who met the CARTITUDE-1 eligibility criteria.
		pERC noted that patients should have generally received an anti- CD38 antibody to be eligible for ciltacabtagene autoleucel, but agreed with the clinical experts that there is a time-limited need to consider patients who were not able to access an anti-CD38 antibody.
		The CARTITUDE-1 trial excluded patients who had received an allogeneic stem cell transplant within 6 months before apheresis or an autologous stem cell transplant ≤ 12 weeks before apheresis.
		pERC indicated that patients who have previously received an allogeneic stem cell transplant > 6 months before apheresis or an autologous stem cell transplant > 12 weeks before apheresis could be eligible to receive ciltacabtagene autoleucel.
Selinexor (Xpovio) + bortezomib (Velcade) + dexamethasone	August 17, 2022	pERC recommends that selinexor in combination with bortezomib and dexamethasone (SVd) be reimbursed for the treatment of adult patients with multiple myeloma who have received at least one prior therapy if the following conditions are met:
		 Adult (≥ 18 years) patients who have all of the following: Histologically confirmed multiple myeloma received at least one prior therapy

	Detect	
Generic name	Date of	Recommendation and guidance on treatment
(brand name)	recommendation	 sequencing SVd should only be prescribed by clinicians with expertise and experience in all of the following: the management of patients with multiple myeloma the adverse effects associated with selinexor Selinexor should only be prescribed and reimbursed in
		combination with bortezomib and dexamethasone. As per the BOSTON trial, prior treatment with bortezomib or other proteasome inhibitor (PI) should be permitted, provided all of the following criteria are met:
		 Best response achieved with prior bortezomib at any time was ≥ partial response (PR) and the last PI therapy (alone or in combination) was ≥ PR Patient did not discontinue bortezomib due to grade ≥ 3 related toxicity
		 Must have had a PI treatment-free interval of at least 6 months prior to the first day of SVd.
		Based on clinical expert opinion, patients with plasma cell leukemia and systemic light chain amyloidosis should be permitted to receive SVd as these patients would be treated in clinical practice and could receive benefit from therapy with SVd.
		Guidance on sequencing:
		 pERC does not anticipate SVd will displace previous and subsequent lines of therapies that are reimbursed; rather, pERC agreed with the clinical experts that daratumumab-containing regimens will likely shift to first line for transplant-ineligible patients. pERC noted that bortezomib-refractory would likely preclude reimbursement of other bortezomib-containing regimen options.
		• pERC agreed with the clinical experts that SVd could be administered to patients in the second line or later, but that other treatment options may be preferred. pERC highlighted if DRd was used in frontline transplant-ineligible patients, SVd is a potential second-line option for these patients. Other funded options are Pd, CyBord, and Kd.
		 pERC agreed with the clinical experts that patients who are refractory to bortezomib would be unlikely to respond to therapy with SVd. pERC felt that, as per the BOSTON trial, prior treatment with bortezomib or other PI should be permitted, provided all of the following criteria are met:
		 best response achieved with prior bortezomib at any time was at least a partial response, and with the last PI therapy (alone or in combination) was at least a partial response
		 the patient did not discontinue bortezomib due to grade 3 or higher related toxicity

Generic name	Date of	Recommendation and guidance on treatment
(brand name)	recommendation	sequencing
		must have had a PI treatment-free interval of at least 6 months before the first day of SVd.
Isatuximab (Sarclisa) + carfilzomib (Kyprolis) + dexamethasone	February 15, 2022	pERC recommends that isatuximab combined with carfilzomib and dexamethasone (IsaKd) be reimbursed for the treatment of adult patients with relapsed or refractory MM who have received 1–3 prior lines of therapy, and the following conditions met:
		 measurable disease received at least 1 prior line of therapy good performance status must not:
		 have prior treatment with antiCD38 mab be refractory to carfilzomib have a LVEF < 40%. Treatment should be discontinued if:
		 evidence of disease progression (IMWG) unacceptable toxicity despite dose modification pERC also called for a reduction in price.
		• pERC agreed with the clinical experts that the preferred regimen depends on what the patient has received previously. If a patient experienced disease progression on a lenalidomide-based regimen in the first-line setting, then IsaKd and DVd are available options.
		• pERC agreed with the clinical experts that it is preferential to give an anti-CD38 as soon as possible, and therefore second-line IsaKd is preferred over third-line IsaPd for those who have not had a CD38 mAb.
		• pERC agreed with the clinical experts that there is currently no evidence to support sequencing of isatuximab and daratumumab.
		pERC agreed with the clinical experts that there is currently no evidence in support of sequencing IsaKd and IsaPd.
Isatuximab (Sarclisa) + pomalidomide (Pomalyst) + dexamethasone	<u>April 1, 2021</u>	pERC conditionally recommends the reimbursement of isatuximab in combination with pomalidomide and dexamethasone (IsaPd) in patients with relapsed or refractory MM who have received at least 2 prior lines of therapy including lenalidomide and a PI, if the following conditions are met:
		 cost-effectiveness improved to an acceptable level
		• feasibility of adoption (budget impact) being assessed. Eligible patients include adults with RRMM who have failed treatment on lenalidomide and a PI, administered either alone or in combination in any prior line of treatment, have disease that was refractory to the last line of treatment received, and good performance status. Treatment should be continued until acceptable toxicity or disease progression.
		Optimal sequencing of IsaPd with other therapies for RRMM including daratumumab: pERC noted that the eligibility criteria in the ICARIA-MM trial included patients who had previous treatment with but were not refractory to an anti-CD38 mAb, but that only 1 patient in the IsaPd treatment group of the trial had prior exposure to an anti-CD38

Conorio nomo	Date of	Recommendation and guidance on treatment
Generic name (brand name)	recommendation	sequencing
		mAb (i.e., daratumumab). In the absence of evidence, pERC concluded that the efficacy of IsaPd in eligible patients who have received at least 2 prior lines of therapy that includes daratumumab is unknown. pERC also concluded that due to the absence of evidence on sequencing of IsaPd and currently available treatments for RRMM, no informed recommendation on optimal sequencing could be made. pERC recognized that jurisdictions would need to address this issue upon implementation of IsaPd reimbursement and noted that collaboration among jurisdictions to develop a common approach to sequencing would be of value.
Pomalidomide (Pomalyst) + bortezomib (Velcade) + dexamethasone	September 18, 2019	pERC conditionally recommends the reimbursement of pomalidomide in combination with dexamethasone and bortezomib (PVd) for the treatment of adults with relapsed or refractory MM who have had at least 1 prior regimen including lenalidomide, if the following condition, cost-effectiveness being improved to an acceptable level, is met. Patients should have good performance status and treatment should be continued until disease progression or unacceptable toxicity. pERC concluded that the optimal sequencing of PVd and other treatments now available for the treatment of MM is currently unknown. pERC was therefore unable to make an evidence- informed recommendation on sequencing. However, pERC recognized that provinces would need to address this issue upon implementation of pomalidomide reimbursement and noted that collaboration among provinces to develop a common approach would be of value.
Daratumumab (Darzalex) + lenalidomide (Revlimid) or bortezomib (Velcade) + dexamethasone	October 5, 2017	pERC recommends the reimbursement of daratumumab in combination with lenalidomide and dexamethasone (DRd) or bortezomib and dexamethasone (DVd) for treatment of patients with MM with good performance status who have received at least 1 prior therapy, conditional on the cost-effectiveness being substantially improved and adoption feasibility being addressed. pERC noted that daratumumab should be continued until disease progression or unacceptable toxicity. pERC concluded that the optimal sequencing of daratumumab plus lenalidomide-dexamethasone or bortezomib-dexamethasone and other treatments now available for the treatment of MM is currently unknown. pERC noted the opinion of the pCODR CGP that daratumumab in combination with lenalidomide-dexamethasone or bortezomib-dexamethasone may be a favourable second-line option over triplet therapy with carfilzomib; however, the committee acknowledged that there is no appropriate treatment sequence for daratumumab and carfilzomib for the treatment of MM after failure of 1 prior therapy. Therefore, pERC was unable to make an evidence-informed recommendation on sequencing of treatments for RRMM. However, pERC recognized that provinces would need to address this issue upon implementation of daratumumab reimbursement and noted that collaboration among provinces to develop a common approach would be of value.

Generic name	Date of recommendation	Recommendation and guidance on treatment sequencing
(brand name) Carfilzomib (Kyprolis) + dexamethasone	March 30, 2017	pERC recommends reimbursement of carfilzomib in combination with dexamethasone for patients with relapsed MM with a good performance status who have received 1 to 3 prior treatments, on the condition that the cost-effectiveness be improved to an acceptable level.
		pERC concluded that optimal sequencing of carfilzomib plus dexamethasone and other treatments now available for the treatment of MM is currently unknown. pERC was therefore unable to make an evidence-informed recommendation on sequencing. However, pERC recognized that provinces would need to address this issue upon implementation of carfilzomib reimbursement and noted that collaboration among provinces to develop a common approach would be of value. pERC acknowledged that carfilzomib plus dexamethasone would be an alternative therapy for patients who are ineligible to receive triplet therapy and not an add-on to the existing sequence of treatments.
Carfilzomib (Kyprolis) + lenalidomide (Revlimid) + dexamethasone	November 11, 2016	 pERC recommends reimbursement of carfilzomib in combination with lenalidomide and dexamethasone for patients with MM who have received at least 1 prior treatment, on condition that the cost-effectiveness be improved to an acceptable level. Patients must not have had disease progression during treatment with bortezomib or if previously treated with lenalidomide and dexamethasone patients must not have: discontinued therapy because of adverse effects disease progression during the first 3 months of treatment, or
		 progression at any time during treatment if lenalidomide plus dexamethasone was their most recent treatment.
		Treatment should be in patients who have good performance status and are deemed to have adequate renal function. Treatment with carfilzomib should continue until disease progression or unacceptable toxicity, up to a maximum of 18 cycles.
		pERC concluded that the optimal sequencing of carfilzomib plus lenalidomide-dexamethasone and other treatments now available for the treatment of MM is currently unknown. pERC was therefore unable to make an evidence-informed recommendation on sequencing. However, pERC recognized that provinces would need to address this issue upon implementation of carfilzomib reimbursement and noted that collaboration among provinces to develop a common approach would be of value.
Pomalidomide (Pomalyst) + dexamethasone	<u>July 31, 2014</u>	pERC recommends funding pomalidomide (Pomalyst) in patients with relapsed and/or refractory MM who have previously failed at least 2 treatments, including both bortezomib and lenalidomide, and demonstrated disease progression on the last treatment, conditional on the cost-effectiveness being improved to an acceptable level. Pomalidomide should also be an option in rare instances where bortezomib is contraindicated, or when patients are intolerant to it but, in all cases, patients should have failed lenalidomide. pERC made this recommendation because it was satisfied that there is a net clinical benefit of pomalidomide in this setting. However, at the submitted price and based on the Economic Panel's range of best estimates of the incremental cost-

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		effectiveness ratio, pomalidomide could not be considered cost- effective compared with best supportive care.
Idecabtagene vicleucel (Abecma)	November 12, 2021	CADTH recommends that Abecma should not be reimbursed by public drug plans for the treatment of MM.
Daratumumab (Darzalex)	December 1, 2016	pERC does not recommend daratumumab for the treatment of patients with MM who 1) have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or 2) have failed or are intolerant to a PI and have failed or are intolerant to an IMiD.


ASCT = autologous stem cell transplant; CGP = clinical guidance panel; DCyBord = daratumumab-cyclophosphamide-bortezomib-dexamethasone; DRd = daratumumablenalidomide-dexamethasone; DVd = daratumumab-bortezomib-dexamethasone; DVMp = daratumumab-bortezomib-melphalan-prednisone; IsaKd = isatuximabcarfilzomib-dexamethasone; IsaPd = isatuximab-pomalidomide-dexamethasone; KRd = carfilzomib-lenalidomide-dexamethasone; LVEF = left ventricular ejection fraction; MM = multiple myeloma; Pd = pomalidomide-dexamethasone; PVd = pomalidomide-dexamethasone-bortezomib; R = lenalidomide; Rd = lenalidomide-dexamethasone; RVd = lenalidomide-bortezomib-dexamethasone; SVd = Selinexor-bortezomib-dexamethasone; V = bortezomib; Vd = bortezomib-dexamethasone.Cilta-cel = ciltacabtagene autoleucel; PI = protease inhibitor; IMiD = immunomodulatory drug

Table 2: CADTH Implementation Advice Panels on Multiple Myeloma

Date of publication	Implementation Advice
<u>May 2022</u>	The panel advises that lenalidomide-bortezomib-dexamethasone (RVd) should be considered as an option for induction therapy in patients with multiple myeloma who are eligible for a transplant.
	The panel advises that carfilzomib-lenalidomide-dexamethasone (KRd) can be sequenced before or after an anti-CD38-based regimen.
	The panel advises that isatuximab-containing regimens would be important second-line options, particularly for patients who are eligible for transplant, contingent on them being funded by public payers.
	The panel advises that both pomalidomide-dexamethasone (Pd) and carfilzomib-dexamethasone (Kd) backbones should be available as sequential treatment options after failure of an anti-CD38-containing regimen.
	The panel advises that Pd or pomalidomide-cyclophosphamide-dexamethasone (PCd) are valid options after failure of first-line lenalidomide-bortezomib-dexamethasone (RVd).

Provisional Funding Algorithm

Figure 1: Provisional Funding Algorithm Diagram for Multiple Myeloma



^c only if also sensitive to R & V

^d must have a proteasome inhibitor treatment-free interval of at least 6 months before 1st day of SVd

^e If no prior treatment with any therapy that targets BCMA or any CAR-T cell therapy.

^f If no prior treatment with any therapy that targets BCMA.

Notes:

1) Patients with drug resistance cannot be re-treated with same drug(s)

2) Cyclophosphamide may be added to Kd, Pd and Rd

3) PVd is not represented in the algorithm as it is not commonly used or a standard of care; PVd has been recommended by pCODR for relapsed or refractory multiple myeloma in patients who have received at least 1 prior treatment regimen including R

Legend

Therapy funded across most jurisdictions	Therapy funding under review for funding (pCPA or province/cancer agency)
--	---

ASCT = autologous stem cell transplant; CGP = clinical guidance panel; DCyBord = daratumumab-cyclophosphamide-bortezomib-dexamethasone; DRd = daratumumablenalidomide-dexamethasone; DVd = daratumumab-bortezomib-dexamethasone; DVMp = daratumumab-bortezomib-melphalan-prednisone; IsaKd = isatuximabcarfilzomib-dexamethasone; IsaPd = isatuximab-pomalidomide-dexamethasone; KRd = carfilzomib-lenalidomide-dexamethasone; LVEF = left ventricular ejection fraction; MM = multiple myeloma; Pd = pomalidomide-dexamethasone; PVd = pomalidomide-dexamethasone-bortezomib; R = lenalidomide; Rd = lenalidomide-dexamethasone; RVd = lenalidomide-bortezomib-dexamethasone; SVd = Selinexor-bortezomib-dexamethasone; V = bortezomib; Vd = bortezomib-dexamethasone.Cilta-cel = ciltacabtagene autoleucel; PI = protease inhibitor; IMiD = immunomodulatory drug

Description of the Provisional Funding Algorithm

Figure 1 depicts the provisional funding algorithm proposed. Note that this diagram is a summary representation of the drug funding options for the condition of interest. It is not a treatment algorithm; it is neither meant to detail the full clinical management of each patient nor the provision of each drug regimen. The diagram may not contain a comprehensive list of all available treatments, and some drugs may not be funded in certain provinces. All drugs are subject to explicit funding criteria, which may also vary between provinces. Readers are invited to refer to the individual drug entries on the CADTH website for more details.

First-Line Setting

Patients who are eligible for an autologous stem cell transplant can receive induction therapy with either cyclophosphamide-bortezomib-dexamethasone (CyBord) or lenalidomide-bortezomib-dexamethasone (RVd), if funded by the jurisdictions. After transplant, maintenance with lenalidomide is available. Patients who are ineligible for transplant can be given CyBord or lenalidomide-dexamethasone (Rd) (with or without daratumumab), RVd or daratumumab-bortezomib-melphalan-prednisone (DVMp).

Relapsed or Refractory

Treatment in the relapsed or refractory setting depends on response to prior therapies. As a rule, patients with drug resistance cannot be treated again with the same drug, except for dexamethasone, which is found in all regimens. Cyclophosphamide may be added to some regimens such as pomalidomide-dexamethasone (Pd), carfilzomib-dexamethasone (Kd), and lenalinomide-dexamethasone (Rd).

Second-line setting

In patients who are sensitive to R (lenalidomide), their options include the following:

daratumumab-lenalidomide-dexamethasone (DRd) or isatuximab-carfilzomibdexamethasone (IsaKd) if the patient is not resistant to an anti-CD38 biologic, lenalidomidedexamethasone (Rd), , carfilzomib-lenalidomide-dexamethasone (KRd) only if the patient is also sensitive to bortezomib (V), carfilzomib-dexamethasone (Kd), or selinexor-bortezomibdexamethasone (SVd). For patients to receive SVD, they must have a proteasome inhibitor treatment-free interval of at least 6 months before the first day.

In patients who are sensitive to V (bortezomib), their options include the following:

Daratumumab-bortezomib-dexamethasone (DVd) or isatuximab-carfilzomib-dexamethasone (IsaKd) if the patient is not resistant to an anti-CD38 biologic, carfilzomib-dexamethasone (Kd) or selinexor-bortezomib-dexamethasone (SVd). For patients to receive SVD, they must have a proteasome inhibitor treatment-free interval of at least 6 months before the first day.

In patients who are resistant to R (lenalidomide) and V (bortezomib), their options include the following:

isatuximab-pomalidomide-dexamethasone (IsaPd) or isatuximab-carfilzomib-dexamethasone if not resistant to an anti-CD38 biologic, carfilzomib-dexamethasone, or pomalidomide-dexamethasone (Pd).

Third-line setting

In patients who are resistant to R (lenalidomide) and V (bortezomib), their options include the following:

isatuximab-pomalidomide-dexamethasone (IsaPd) or isatuximab-carfilzomib-dexamethasone if not resistant to an anti-CD38 biologic, carfilzomib-dexamethasone, or pomalidomide-dexamethasone (Pd).

In patients who are sensitive to V (bortezomib) but not R (lenalidomide), their options include the following:

Daratumumab-bortezomib-dexamethasone (DVd) or isatuximab-carfilzomib-dexamethasone (IsaKd) if the patient is not resistant to an anti-CD38 biologic, carfilzomib-dexamethasone (Kd), bortezomib-dexamethasone (Vd) or selinexor-bortezomib-dexamethasone (SVd). For patients to receive SVd, they must have a proteasome inhibitor treatment-free interval of at least 6 months before the first day.

In patients who are sensitive to R (lenalidomide) but not V (bortezomib), their options include the following:

daratumumab-lenalidomide-dexamethasone (DRd) or isatuximab-carfilzomibdexamethasone (IsaKd) if the patient is not resistant to an anti-CD38 biologic, lenalidomidedexamethasone (Rd), or carfilzomib-dexamethasone (Kd).

Fourth-line setting:

In patients who are resistant to anti-CD38 biologic, R (lenalidomide) and V (bortezomib), their options include either pomalidomide-dexamethasone, carfilzomib-dexamethasone, teclistamab, elranatamab, ciltacabtagene autoleucel or other alkylating agents.

In patients who are sensitive to V (bortezomib) but not to anti-CD38 biologic or R (lenalidomide), the option includes selinexor-bortezomib-dexamethasone (SVd) or carfilzomib-dexamethasone (Kd). For patients to receive SVd, they must have a proteasome inhibitor treatment-free interval of at least 6 months before the first day.

In patients who have received anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitor (PI) and refractory to last treatment, their options include teclistamab, elranatamab or ciltacabtagene autoleucel.

For patients to receive ciltacabtagene autoleucel therapy, they must not have prior treatment with any therapy that targets b-cell maturation antigen (BCMA) or any CAR-T cellular therapy.

For patients to receive elranatamab, they must not have prior treatment with any therapy that targets BCMA.

Note that pomalidomide-dexamethasone-bortezomib (PVd) is not represented in the algorithm as it is not commonly used or a standard of care; However, PVd has been recommended by pCODR for relapse or refractory multiple myeloma in patients who have received at least 1 prior treatment regimen include R (lenalidomide).